Making Decisions about Dietary Therapy in Inflammatory Bowel Disease
Abstract
1. Introduction
2. Dietary Therapy
3. Medical Therapy
4. Motivations to Choose Dietary Therapy
5. Fostering Informed Choice of Dietary Therapy
6. Patient Empowerment, Activation, and Preferences
7. Shared Decision-Making
8. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Nurmi, E.; Haapamäki, J.; Paavilainen, E.; Rantanen, A.; Hillilä, M.; Arkkila, P. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand. J. Gastroenterol. 2013, 48, 51–57. [Google Scholar] [CrossRef] [PubMed]
- Halfvarson, J.; Bodin, L.; Tysk, C.; Lindberg, E.; Järnerot, G. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003, 124, 1767–1773. [Google Scholar] [CrossRef]
- Jostins, L.; Ripke, S.; Weersma, R.K.; Duerr, R.H.; McGovern, D.P.; Hui, K.Y.; Lee, J.C.; Schumm, L.P.; Sharma, Y.; Anderson, C.A.; et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119–124. [Google Scholar] [CrossRef] [PubMed]
- Crowley, E.; Warner, N.; Pan, J.; Sam, K.; Elkadri, A.; Fiedler, K.; Foong, J.; Turinsky, A.L.; Bronte-Tinkew, D.; Zhang, S.; et al. Prevalence and clinical features of inflammatory bowel diseases associated with monogenic variants, identified by whole-exome sequencing in 1000 children at a single center. Gastroenterology 2020, 158, 2208–2220. [Google Scholar] [CrossRef]
- Barreiro-de Acosta, M.; Alvarez Castro, A.; Souto, R.; Iglesias, M.; Lorenzo, A.; Dominguez-Muñoz, J.E. Emigration to western industrialized countries: A risk factor for developing inflammatory bowel disease. J. Crohn’s Colitis 2011, 5, 566–569. [Google Scholar] [CrossRef]
- Li, X.; Sundquist, J.; Hemminki, K.; Sundquist, K. Risk of inflammatory bowel disease in first- and second-generation immigrants in SwedenA nationwide follow-up study. Inflamm. Bowel Dis. 2011, 17, 1784–1791. [Google Scholar] [CrossRef]
- Damas, O.M.; Avalos, D.J.; Palacio, A.M.; Gomez, L.; Quintero, M.A.; Deshpande, A.R.; Sussman, D.A.; McCauley, J.L.; Lopez, J.; Schwartz, S.J.; et al. Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba. Aliment. Pharmacol. Ther. 2017, 46, 303–309. [Google Scholar] [CrossRef]
- Benchimol, E.I.; Mack, D.R.; Guttmann, A.; Nguyen, G.C.; To, T.; Mojaverian, N.; Quach, P.; Manuel, G.D. Inflammatory bowel disease in immigrants to Canada and their children: A population-based cohort study. Am. J. Gastroenterol. 2015, 110, 553–563. [Google Scholar] [CrossRef]
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018, 390, 2769–2778. [Google Scholar] [CrossRef]
- Chassaing, B.; Koren, O.; Goodrich, J.K.; Poole, A.C.; Srinivasan, S.; Ley, R.E.; Gewirtz, A.T. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519, 92–96. [Google Scholar] [CrossRef]
- Devkota, S.; Wang, Y.; Musch, M.W.; Leone, V.; Fehlner-Peach, H.; Nadimpalli, A.; Antonopoulos, D.A.; Jabri, B.; Chang, E.B. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10 −/− mice. Nature 2012, 487, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Jones, C.M.A.; Connors, J.; Dunn, K.A.; Bielawski, J.P.; Comeau, A.M.; Langille, M.G.I.; van Limbergen, J. Bacterial taxa and functions are predictive of sustained remission following exclusive enteral nutrition in pediatric Crohn’s disease. Inflamm. Bowel Dis. 2020, 26, 1026–1037. [Google Scholar] [CrossRef] [PubMed]
- Suskind, D.L.; Cohen, S.A.; Brittnacher, M.J.; Wahbeh, G.; Lee, D.; Shaffer, M.L.; Braly, K.; Hayden, H.S.; Klein, J.; Gold, B.; et al. Clinical and fecal microbial changes with diet therapy in active inflammatory bowel disease. J. Clin. Gastroenterol. 2018, 52, 155–163. [Google Scholar] [CrossRef] [PubMed]
- Levine, A.; Sigall Boneh, R.; Wine, E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 2018, 67, 1726–1738. [Google Scholar] [CrossRef]
- Siegel, C.A.; Siegel, L.S.; Hyams, J.S.; Kugathasan, S.; Markowitz, J.; Rosh, J.R.; Leleiko, N.; Mack, D.R.; Crandall, W.; Evans, J. Real-time tool to display the predicted disease course and treatment response for children with Crohn’s disease. Inflamm. Bowel Dis. 2011, 17, 30–38. [Google Scholar] [CrossRef] [PubMed]
- Hazlewood, G.S.; Pokharel, G.; Deardon, R.; Marshall, D.A.; Bombardier, C.; Tomlinson, G.; Ma, C.; Seow, C.H.; Panaccione, R.; Kaplan, G.G.; et al. Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment. PLoS ONE 2020, 15, e0227635. [Google Scholar] [CrossRef]
- Lipstein, E.A.; Lovell, D.J.; Denson, L.A.; Kim, S.C.; Spencer, C.; Ittenbach, R.F.; Britto, M.T. High levels of decisional conflict and decision regret when making decisions about biologics. J. Pediatr. Gastroenterol. Nutr. 2016, 63, e176–e181. [Google Scholar] [CrossRef]
- Gu, P.; Feagins, L.A. Dining with inflammatory bowel disease: A review of the literature on diet in the pathogenesis and management of IBD. Inflamm. Bowel Dis. 2020, 26, 181–191. [Google Scholar] [CrossRef]
- Zallot, C.; Quilliot, D.; Chevaux, J.-B.; Peyrin-Biroulet, C.; Gueant-Rodriguez, R.M.; Freling, E.; Collet-Fenetrier, B.; Williet, N.; Ziegler, O.; Bigard, M.; et al. Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm. Bowel Dis. 2013, 19, 66–72. [Google Scholar] [CrossRef]
- Limdi, J.K.; Aggarwal, D.; McLaughlin, J.T. Dietary practices and beliefs in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2016, 22, 164–170. [Google Scholar] [CrossRef]
- Shoda, R.; Matsueda, K.; Yamato, S.; Umeda, N. Epidemiologic analysis of Crohn disease in Japan: Increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr. 1996, 63, 741–745. [Google Scholar] [CrossRef] [PubMed]
- Limketkai, B.N.; Iheozor-Ejiofor, Z.; Gjuladin-Hellon, T.; Parian, A.; Matarese, L.E.; Bracewell, K.; MacDonald, J.K.; Gordon, M.; Mullin, G.E. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. Cochrane Database Syst. Rev. 2019, 2, CD012839. [Google Scholar] [CrossRef] [PubMed]
- Hou, J.K.; Lee, D.; Lewis, J. Diet and inflammatory bowel disease: Review of patient-targeted recommendations. Clin. Gastroenterol. Hepatol. 2014, 12, 1592–1600. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.; Gupta, A.; Kedia, S.; Agarwal, S.; Singh, N.; Goyal, S.; Jain, S.; Gupta, V.; Sahu, P.; Vuyyuru, S.K.; et al. Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease. Intest. Res. 2020. [Google Scholar] [CrossRef]
- Swaminath, A.; Feathers, A.; Ananthakrishnan, A.N.; Falzon, L.; Li Ferry, S. Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment. Pharmacol. Ther. 2017, 46, 645–656. [Google Scholar] [CrossRef]
- Borrelli, O.; Cordischi, L.; Cirulli, M.; Paganelli, M.; Labalestra, V.; Uccini, S.; Russo, P.M.; Cucchiara, S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: A randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 2006, 4, 744–753. [Google Scholar] [CrossRef]
- Issokson, K. Living on liquids: Surviving and thriving on exclusive enteral nutrition. Am. J. Gastroenterol. 2017, 112, 1491–1492. [Google Scholar] [CrossRef]
- Ruemmele, F.M.; Veres, G.; Kolho, K.L.; Griffiths, A.; Levine, A.; Escher, J.C.; Amil Dias, J.; Barabino, A.; Braegger, C.P.; Bronsky, J.; et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J. Crohns Colitis. 2014, 8, 1179–1207. [Google Scholar] [CrossRef]
- Mack, D.R.; Benchimol, E.I.; Critch, J.; deBruyn, J.; Tse, F.; Moayyedi, P.; Church, P.; Deslandres, C.; El-Matary, W.; Huynh, H.; et al. Canadian association of gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn’s disease. Gastroenterology 2019, 157, 320–348. [Google Scholar] [CrossRef]
- Lawley, M.; Wu, J.W.; Navas-López, V.M.; Huynh, H.Q.; Carroll, M.W.; Chen, M.; Medvedev, P.; Day, A.S.; Hussey, S.; Sigall-Boneh, R.; et al. Global variation in use of enteral nutrition for pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2018, 67, e22–e29. [Google Scholar] [CrossRef]
- Britto, S.; Kellermayer, R. Carbohydrate monotony as protection and treatment for inflammatory bowel disease. J. Crohns Colitis. 2019, 13, 942–948. [Google Scholar] [CrossRef] [PubMed]
- Kaakoush, N.O.; Day, A.S.; Leach, S.T.; Lemberg, D.A.; Nielsen, S.; Mitchell, H.M. Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed Crohn’s disease. Clin. Transl. Gastroenterol. 2015, 6, e71. [Google Scholar] [CrossRef] [PubMed]
- Narula, N.; Dhillon, A.; Zhang, D.; Sherlock, M.E.; Tondeur, M.; Zachos, M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2018, 4, CD000542. [Google Scholar] [CrossRef]
- Wall, C.L.; McCombie, A.; Mulder, R.; Day, A.S.; Gearry, R.B. Adherence to exclusive enteral nutrition by adults with active Crohn’s disease. ease. J. Hum. Nutr. Diet. 2020. [Google Scholar] [CrossRef] [PubMed]
- Mehta, P.; Pan, Z.; Furuta, G.T.; Kim, D.Y.; de Zoeten, E. Parent perspectives on exclusive enteral nutrition for the treatment of pediatric Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 2020. [Google Scholar] [CrossRef]
- Afzal, N.A.; Zaag-Loonen, H.J.V.D.; Arnaud-Battandier, F.; Davies, S.; Murch, S.; Derkx, B.; Heuschkel, R.; Fell, J.M. Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment. Pharmacol. Ther. 2004, 20, 167–172. [Google Scholar] [CrossRef]
- Yang, H.; Feng, R.; Li, T.; Xu, S.; Hao, X.; Qiu, Y.A.; Chen, M. Systematic review with meta-analysis of partial enteral nutrition for the maintenance of remission in Crohn’s disease. Nutr. Res. 2020, 81, 7–18. [Google Scholar] [CrossRef]
- Lee, D.; Baldassano, R.N.; Otley, A.R.; Albenberg, L.; Griffiths, A.M.; Compher, C.; Chen, E.Z.; Li, H.; Gilroy, E.; Nessel, L.; et al. Comparative effectiveness of nutritional and biological therapy in North American children with active crohn’s disease. Inflamm. Bowel Dis. 2015, 21, 1786–1793. [Google Scholar] [CrossRef]
- Sigall-Boneh, R.; Pfeffer-Gik, T.; Segal, I.; Zangen, T.; Boaz, M.; Levine, A. Partial enteral nutrition with a Crohn’s disease exclusion diet is effective for induction of remission in children and young adults with Crohn’s disease. Inflamm. Bowel Dis. 2014, 20, 1353–1360. [Google Scholar] [CrossRef]
- Boneh, R.S.; Shabat, C.S.; Yanai, H.; Chermesh, I.; Ben Avraham, S.; Boaz, M.; Levine, A.; Ben-Avraham, S. Dietary therapy with the Crohn’s disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy. J. Crohns Colitis. 2017, 11, 1205–1212. [Google Scholar] [CrossRef]
- Sigall Boneh, R.; Van Limbergen, J.; Wine, E.; Assa, A.; Shaoul, R.; Milman, P.; Cohen, S.; Kori, M.; Peleg, S.; On, A.; et al. Dietary therapies induce rapid response and remission in pediatric patients with active Crohn’s disease. Clin. Gastroenterol. Hepatol. 2020. [Google Scholar] [CrossRef] [PubMed]
- Levine, A.; Wine, E.; Assa, A.; Boneh, R.S.; Shaoul, R.; Kori, M.; Cohen, S.; Peleg, S.; Shamaly, H.; On, A.; et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 2019, 157, 440–450.e8. [Google Scholar] [CrossRef] [PubMed]
- Svolos, V.; Hansen, R.; Nichols, B.; Quince, C.; Ijaz, U.Z.; Papadopoulou, R.T.; Edwards, C.A.; Watson, D.; Alghamdi, A.; Brejnrod, A.; et al. Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology 2019, 156, 1354–1367.e6. [Google Scholar] [CrossRef] [PubMed]
- Hwang, C.; Ross, V.; Mahadevan, U. Popular exclusionary diets for inflammatory bowel disease: The search for a dietary culprit. Inflamm. Bowel Dis. 2014, 20, 732–741. [Google Scholar] [CrossRef] [PubMed]
- Suskind, D.L.; Wahbeh, G.; Cohen, S.A.; Damman, C.J.; Klein, J.; Braly, K.; Shaffer, M.; Lee, D. Patients perceive clinical benefit with the specific carbohydrate diet for inflammatory bowel disease. Dig. Dis. Sci. 2016, 61, 3255–3260. [Google Scholar] [CrossRef]
- Wahbeh, G.T.; Ward, B.T.; Lee, D.Y.; Giefer, M.J.; Suskind, D.L. Lack of mucosal healing from modified specific carbohydrate diet in pediatric patients with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2017, 65, 289–292. [Google Scholar] [CrossRef]
- Halmos, E.P.; Power, V.A.; Shepherd, S.J.; Gibson, P.R.; Muir, J.G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014, 146, 67–75.e5. [Google Scholar] [CrossRef]
- Gibson, P.R.; Shepherd, S.J. Personal view: Food for thought—western lifestyle and susceptibility to Crohn’s disease. The FODMAP hypothesis. Aliment. Pharmacol. Ther. 2005, 21, 1399–1409. [Google Scholar] [CrossRef]
- Tursi, A.; Giorgetti, G.M.; Brandimarte, G.; Elisei, W. High prevalence of celiac disease among patients affected by Crohn’s disease. Inflamm. Bowel Dis. 2005, 11, 662–666. [Google Scholar] [CrossRef]
- Chiba, M.; Abe, T.; Tsuda, H.; Sugawara, T.; Tsuda, S.; Tozawa, H.; Fujiwara, K.; Imai, H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J. Gastroenterol. 2010, 16, 2484–2495. [Google Scholar] [CrossRef]
- Albenberg, L.; Brensinger, C.M.; Wu, Q.; Gilroy, E.; Kappelman, M.D.; Sandler, R.S.; Lewis, J.D. A diet low in red and processed meat does not reduce rate of Crohn’s disease flares. Gastroenterology 2019, 157, 128–136.e5. [Google Scholar] [CrossRef] [PubMed]
- Konijeti, G.G.; Kim, N.; Lewis, J.D.; Groven, S.; Chandrasekaran, A.; Grandhe, S.; Diamant, C.; Singh, E.; Oliveira, G.; Wang, X.; et al. Efficacy of the autoimmune protocol diet for inflammatory bowel disease. Inflamm. Bowel Dis. 2017, 23, 2054. [Google Scholar] [CrossRef] [PubMed]
- Scribano, M.L. Adverse events of IBD therapies. Inflamm. Bowel Dis. 2008, 14 (Suppl. 2), S210–S211. [Google Scholar] [CrossRef]
- Herfarth, H.H.; Kappelman, M.D.; Long, M.D.; Isaacs, K.L. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm. Bowel Dis. 2016, 22, 224–233. [Google Scholar] [CrossRef] [PubMed]
- Axelrad, J.E.; Roy, A.; Lawlor, G.; Korelitz, B.; Lichtiger, S. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. World J. Gastroenterol. 2016, 22, 10103–10117. [Google Scholar] [CrossRef] [PubMed]
- Danese, S.; Vuitton, L.; Peyrin-Biroulet, L. Biologic agents for IBD: Practical insights. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 537–545. [Google Scholar] [CrossRef]
- Shivali, U.N.; Sharratt, C.L.; Thomas, T.; Smith, S.C.L.; Iacucci, M.; Moran, G.W.; Ghosh, S.; Bhala, N. Review article: Managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2019, 49, 664–680. [Google Scholar] [CrossRef]
- Chudy-Onwugaje, K.O.; Christian, K.E.; Farraye, F.A.; Cross, R.K. A state-of-the-art review of new and emerging therapies for the treatment of IBD. Inflamm. Bowel Dis. 2019, 25, 820. [Google Scholar] [CrossRef]
- Koning, M.; Ailabouni, R.; Gearry, R.B.; Frampton, C.M.A.; Barclay, M.L. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case–control Study. Inflamm. Bowel Dis. 2013, 19, 767–778. [Google Scholar] [CrossRef]
- Hilsden, R.J.; Scott, C.M.; Verhoef, M.J. Complementary medicine use by patients with inflammatory bowel disease. Am. J. Gastroenterol. 1998, 93, 697–701. [Google Scholar] [CrossRef]
- Kamp, K.J.; Brittain, K. Factors that influence treatment and non-treatment decision making among individuals with inflammatory bowel disease: An integrative review. Patient 2018, 11, 271–284. [Google Scholar] [CrossRef]
- Moser, G.; Tillinger, W.; Sachs, G.; Maier-Dobersberger, T.; Wyatt, J.; Vogelsang, H.; Lochs, H.; Gangl, A. Relationship between the use of unconventional therapies and disease-related concerns: A study of patients with inflammatory bowel disease. J. Psychosom. Res. 1996, 40, 503–509. [Google Scholar] [CrossRef]
- Triggs, C.M.; Munday, K.; Hu, R.; Fraser, A.G.; Gearry, R.B.; Barclay, M.L.; Ferguson, L.R. Dietary factors in chronic inflammation: Food tolerances and intolerances of a New Zealand Caucasian Crohn’s disease population. Mutat. Res. Fund. Mol. Mechan. Mutagen. 2010, 690, 123–138. [Google Scholar] [CrossRef] [PubMed]
- De Vries, J.H.M.; Dijkhuizen, M.; Tap, P.; Witteman, B.J.M. Patient’s dietary beliefs and behaviours in inflammatory bowel disease. Dig. Dis. Sci. 2019, 37, 131–139. [Google Scholar] [CrossRef]
- Vagianos, K.; Clara, I.; Carr, R.; Graff, L.A.; Walker, J.R.; Targownik, L.E.; Lix, L.M.; Rogala, L.; Miller, N.; Bernstein, C.N.; et al. What are adults with inflammatory bowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. J. Parenter. Enteral. Nutr. 2016, 40, 405–411. [Google Scholar] [CrossRef] [PubMed]
- Palant, A.; Koschack, J.; Rassmann, S.; Lucius-Hoene, G.; Karaus, M.; Himmel, W. “And then you start to loose it because you think about Nutella”: The significance of food for people with inflammatory bowel disease—a qualitative study. BMC Gastroenterology 2015, 15, 93. [Google Scholar] [CrossRef]
- Holt, D.Q.; Strauss, B.J.; Moore, G.T. Patients with inflammatory bowel disease and their treating clinicians have different views regarding diet. J. Hum. Nutr. Diet. 2017, 30, 66. [Google Scholar] [CrossRef]
- Jowett, S.L.; Seal, C.J.; Phillips, E.; Gregory, W.; Barton, J.R.; Welfare, M.R. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin. Nutr. 2004, 23, 161–170. [Google Scholar] [CrossRef]
- Vagianos, K.; Bector, S.; McConnell, J.; Bernstein, C.N. Nutrition assessment of patients with inflammatory bowel disease. J. Parenter. Enter. Nutr. 2007, 31, 311–319. [Google Scholar] [CrossRef]
- Imes, S.; Pinchebeck, B.; Thomson, A. Diet counseling modifies nutrient intake of patients with Crohn’s disease. J. Am. Diet. Assoc. 1987, 87, 457–462. [Google Scholar]
- Catalán-Serra, I.; Huguet-Malavés, J.M.; Mínguez, M.; Torrella, E.; Paredes, J.M.; Vazquez, N.; Ramirez, J.J.; Calvo, F.; Nos, P.; Gutierrez, A.; et al. Information resources used by patients with inflammatory bowel disease: Satisfaction, expectations and information gaps. Gastroenterol. Hepatol. 2015, 38, 355–363. [Google Scholar] [CrossRef] [PubMed]
- Bernstein, K.I.; Promislow, S.; Carr, R.; Rawsthorne, P.; Walker, J.R.; Bernstein, C.N. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17, 590–598. [Google Scholar] [CrossRef] [PubMed]
- Hung, A.; Kang, N.; Bollom, A.; Wolf, J.L.; Lembo, A. Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Dig. Dis. Sci. 2015, 60, 1883–1888. [Google Scholar] [CrossRef] [PubMed]
- Van der Marel, S.; Duijvestein, M.; Hardwick, J.C.; van den Brink, G.R.; Veenendaal, R.; Hommes, D.W.; Fidder, H.H. Quality of web-based information on inflammatory bowel diseases. Inflamm. Bowel Dis. 2009, 15, 1891–1896. [Google Scholar] [CrossRef]
- Cima, R.R.; Anderson, K.J.; Larson, D.W.; Dozois, E.J.; Hassan, I.; Sandborn, W.J.; Loftus, E.V.; Pemberton, J.H. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm. Bowel Dis. 2007, 13, 1266–1270. [Google Scholar] [CrossRef]
- DiMatteo, M.R.; Reiter, R.C.; Gambone, J.C. Enhancing medication adherence through communication and informed collaborative choice. Heal. Commun. 1994, 6, 253–265. [Google Scholar] [CrossRef]
- Siegel, C.A.; Levy, C.L.; MacKenzie, T.A.; Sands, B.E. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14, 1–6. [Google Scholar] [CrossRef]
- Austin, C.A.; Mohottige, D.; Sudore, R.L.; Smith, A.K.; Hanson, L.C. Tools to promote shared decision making in serious illness: A systematic review. JAMA Intern. Med. 2015, 175, 1213–1221. [Google Scholar] [CrossRef]
- Stacey, D.; Légaré, F.; Lewis, K.; Barry, M.J.; Bennett, C.L.; Eden, K.B.; Holmes-Rovner, M.; Llewellyn-Thomas, H.; Lyddiatt, A.; Thomson, R.; et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database System. Rev. 2017, 4. [Google Scholar] [CrossRef]
- Labonte, R. Health promotion and empowerment: Reflections on professional practice. Heal. Educ. Q. 1994, 21, 253–268. [Google Scholar] [CrossRef]
- Aujoulat, I.; d’Hoore, W.; Deccache, A. Patient empowerment in theory and practice: Polysemy or cacophony? Patient Educ. Couns. 2007, 66, 13–20. [Google Scholar] [CrossRef] [PubMed]
- Pibernik-Okanovic, M.; Prasek, M.; Poljicanin-Filipovic, T.; Pavlic-Renar, I.; Metelko, Z. Effects of an empowerment-based psychosocial intervention on quality of life and metabolic control in type 2 diabetic patients. Patient Educ. Couns. 2004, 52, 193–199. [Google Scholar] [CrossRef]
- Pellino, T.; Tluczek, A.; Collins, M.; Trimborn, S. Increasing self-efficacy through empowerment: Preoperative education for orthopaedic patients. Orthop. Nurs. 1998, 17, 48–51, 54–59. [Google Scholar] [CrossRef] [PubMed]
- Davison, B.J.; Degner, L.F. Empowerment of men newly diagnosed with prostate cancer. Cancer Nurs. 1997, 20, 187–196. [Google Scholar] [CrossRef] [PubMed]
- Fumagalli, L.P.; Radaelli, G.; Lettieri, E.; Bertele’, P.; Masella, C. Patient empowerment and its neighbours: Clarifying the boundaries and their mutual relationships. Heal. Policy 2015, 119, 384–394. [Google Scholar] [CrossRef]
- Kiesler, D.J.; Auerbach, S.M. Optimal matches of patient preferences for information, decision-making and interpersonal behavior: Evidence, models and interventions. Patient Educ. Couns. 2006, 61, 319–341. [Google Scholar] [CrossRef] [PubMed]
- Harrington, J.; Noble, L.M.; Newman, S.P. Improving patients’ communication with doctors: A systematic review of intervention studies. Patient Educ. Couns. 2004, 52, 7–16. [Google Scholar] [CrossRef]
- Van Overbeeke, E.; Janssens, R.; Whichello, C.; Bywall, K.S.; Sharpe, J.; Nikolenko, N.; Phillips, B.S.; Guiddi, P.; Pravettoni, G.; Vergani, L.; et al. Design, conduct, and use of patient preference studies in the medical product life cycle: A multi-method study. Front. Pharmacol. 2019, 10, 1395. [Google Scholar] [CrossRef]
- Bewtra, M.; Johnson, F.R. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: A critical review of quantitative data. Patient 2013, 6, 241–255. [Google Scholar] [CrossRef]
- Lichtenstein, G.R.; Waters, H.C.; Kelly, J.; McDonald, S.S.; Zanutto, E.L.; Hendricks, D.; Rahman, M.I. Assessing drug treatment preferences of patients with Crohn’s disease. Patient-Center Outcome Res. 2010, 3, 113–123. [Google Scholar] [CrossRef]
- Johnson, F.R.; Ozdemir, S.; Mansfield, C.; Hass, S.; Miller, D.W.; Siegel, C.A.; Sands, B.E. Crohn’s disease patients’ risk-benefit preferences: Serious adverse event risks versus treatment efficacy. Gastroenterology 2007, 133, 769–779. [Google Scholar] [CrossRef] [PubMed]
- Hodgkins, P.; Swinburn, P.; Solomon, D.; Yen, L.; Dewilde, S.; Lloyd, A. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: A discrete-choice experiment. Patient 2012, 5, 33–44. [Google Scholar] [CrossRef]
- Gabe, J.; Olumide, G.; Bury, M. ‘It takes three to tango’: A framework for understanding patient partnership in paediatric clinics. Soc. Sci. Med. 2004, 59, 1071–1079. [Google Scholar] [CrossRef] [PubMed]
- Dodds, C.M.; Britto, M.T.; Denson, L.A.; Lovell, D.J.; Saeed, S.; Lipstein, E.A. Physicians’ perceptions of shared decision making in chronic disease and its barriers and facilitators. J. Pediatr. 2016, 171, 307–309.e2. [Google Scholar] [CrossRef]
- Siegel, C.A. Making therapeutic decisions in IBD: The role of patients. Curr. Opin. Gastroenterol. 2009, 25, 334–338. [Google Scholar] [CrossRef]
- O’Connor, A.M.; Wennberg, J.E.; Legare, F.; Llewellyn-Thomas Hilary, A.; Moulton Benjamin, W.; Sepucha Karen, R.; Sodano Andrea, G.; King Jaime, S. Toward the “tipping point”: Decision aids and informed patient choice. Heal. Aff. 2007, 26, 716–725. [Google Scholar] [CrossRef]
- Siegel, C.A. Review article: Explaining risks of inflammatory bowel disease therapy to patients. Aliment. Pharmacol. Ther. 2011, 33, 23–32. [Google Scholar] [CrossRef]
- Fagerlin, A.; Ubel, P.A.; Smith, D.M.; Zikmund-Fisher, B.J. Making numbers matter: Present and future research in risk communication. Am. J. Heal. Behav. 2007, 31, S47–S56. [Google Scholar] [CrossRef]
- Hill, J.; Bird, H.; Johnson, S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: A randomised controlled trial. Ann. Rheum. Dis. 2001, 60, 869–875. [Google Scholar]
- M’Imunya, J.M.; Kredo, T.; Volmink, J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst. Rev. 2012, 5. [Google Scholar] [CrossRef]
- Reyna, V.F. A theory of medical decision making and health: Fuzzy trace theory. Med. Decis. Mak. 2008, 28, 850–865. [Google Scholar] [CrossRef] [PubMed]
IBD Subtype | Location of Study | Main Findings | Author, Year |
---|---|---|---|
n = 244, 72.5% CD, 27.5% UC | Lorraine, France | The majority of participants avoided a certain food and felt food plays an important role in their disease and chance of relapse | Zallot et al., 2013 [19] |
n = 400, 39% CD, 51% UC | Manchester, UK | The majority of participants associated certain foods as being triggers and would deny themselves a food to avoid a relapse | Limdi et al., 2016 [20] |
n = 446, 100% CD | New Zealand | There is great variation in what patients with CD consider a beneficial or detrimental food | Triggs et al., 2010 [63] |
n = 294, 50.3% CD, 49.7% UC | The Netherlands | The majority of participants considered food to play a larger role in disease management and outcome than medication | de Vries et al., 2019 [64] |
n= 256, 52% CD, 48% UC | Manitoba, Canada | The majority of participants did avoid certain foods and their dietary intake demonstrated deficiencies | Vagianos et al., 2016 [65] |
n = 42, 60% CD, 36% UC, 4% Indeterminate IBD | Germany | Nearly all participants felt restricted in their eating behavior and several felt unsupported by their doctors | Palant et al., 2015 [66] |
n = 4, 67% CD, 33% UC | Australia | The majority of participants consider diet important to their IBD; advice given to the patients about diet was diverse, inadequate, and poorly followed | Holt et al., 2016 [67] |
Type of Approach | Benefits | Available Tools | Unmet Needs |
---|---|---|---|
Patient Empowerment and Patient Activation | Increased control of life, group support, increased confidence, larger contribution to the decision-making process | Proven programs for a variety of chronic diseases | Patient empowerment or activation program specific to dietary therapy in IBD. Existing programs may be applied to IBD generally |
Preference Analysis | Determination of perceived values of risk and reward, enhancement of certainty of preferences based on analysis, detection of similarities or differences in patient and provider preferences | Multiple IBD preference analyses exist in various formats | Preference analysis tool specific to dietary therapy in IBD. Existing IBD preference analyses will guide decisions for dietary therapy |
Shared Decision-Making | Patient feels valued, improved transparency and fosters ongoing open communication, improved adherence and confidence in treatment | Well-developed guidance for process in IBD, multiple IBD decision aids in multiple formats | Decision aids for dietary therapy in IBD. SDM process in IBD should be applied, in part, to dietary therapy presently |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Solomon, S.; Park, E.; Picoraro, J.A. Making Decisions about Dietary Therapy in Inflammatory Bowel Disease. Gastrointest. Disord. 2020, 2, 353-365. https://doi.org/10.3390/gidisord2040032
Solomon S, Park E, Picoraro JA. Making Decisions about Dietary Therapy in Inflammatory Bowel Disease. Gastrointestinal Disorders. 2020; 2(4):353-365. https://doi.org/10.3390/gidisord2040032
Chicago/Turabian StyleSolomon, Sydney, Eunie Park, and Joseph A. Picoraro. 2020. "Making Decisions about Dietary Therapy in Inflammatory Bowel Disease" Gastrointestinal Disorders 2, no. 4: 353-365. https://doi.org/10.3390/gidisord2040032
APA StyleSolomon, S., Park, E., & Picoraro, J. A. (2020). Making Decisions about Dietary Therapy in Inflammatory Bowel Disease. Gastrointestinal Disorders, 2(4), 353-365. https://doi.org/10.3390/gidisord2040032